AIGH Capital reports 5.9% Grace Therapeutics (GRCE) ownership stake
Rhea-AI Filing Summary
Grace Therapeutics, Inc. received an amended Schedule 13G/A showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together report beneficial ownership of 907,217 shares of Common Stock, representing 5.9% of the class as of 12/31/2025.
The filing notes an additional 824,742 common shares are issuable upon exercise of warrants that are not currently exercisable because of beneficial ownership limitations. The reporting persons certify the shares were acquired and are held in the ordinary course of business and not to change or influence control of Grace Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Grace Therapeutics (GRCE) does AIGH Capital report owning?
AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together report beneficial ownership of 5.9% of Grace Therapeutics’ common stock. This corresponds to 907,217 shares, as disclosed in the amended Schedule 13G/A with an event date of December 31, 2025.
Who are the reporting persons in the Grace Therapeutics (GRCE) Schedule 13G/A?
The Schedule 13G/A is jointly filed by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman. Hirschman is described as the Managing Member of AIGH Capital Management LLC and president of AIGH Investment Partners LLC, and they are collectively referred to as the reporting persons.
What does the Schedule 13G/A say about AIGH’s intent regarding control of Grace Therapeutics (GRCE)?
The certification states the securities were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held for the purpose or effect of changing or influencing control of Grace Therapeutics, consistent with a passive ownership filing.
What is the event date referenced in this Grace Therapeutics (GRCE) ownership filing?
The Schedule 13G/A lists an event date of December 31, 2025. This date indicates the point as of which the reported beneficial ownership information applies, including the 907,217 shares and corresponding 5.9% ownership of Grace Therapeutics’ outstanding common stock.